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We  have  recently  reported  the  elimination  in  vivo of a  syngeneic  rat  Moloney 
sarcoma (MST) 1 with an established blood supply, by remote intravenous infusion of 
syngeneic splenic effector cells with specificity for the tumor (1). The splenic effector 
cells were effective in vivo only after cytotoxicity of the population was augmented in 
an in vitro mixed lymphocyte tumor cell culture (MLTC).  In this paper, we present 
data  on  the  elimination of an  established  Moloney  sarcoma  with  a  blood  supply, 
ranging from  1 to 7 cm in Diam, by infusion of varying numbers of specific effector 
cells. The specific effector cells were a  subset of T  blast cells, W3/25 +  and W3/13 + 
(2),  as  detected  by  monoclonal  antibodies to  rat  T  antigens,  and  they  apparently 
functioned as amplifier or helper cells in the tumor-bearing host. A  W3/25-  popula- 
tion, a  melange of T  cells, null cells, macrophages, and  B  cells, was associated with 
enhancement  of tumor in vivo. 
Materials  and  Methods 
Rats.  3-mo-old BN females were used as donors of spleen cells and as test animals bearing 
an  established tumor.  They were obtained from  the breeding colony of Scripps Clinic and 
Research Foundation (La Jolla, Calif.) 
Tumors.  MST- 1 is a rat Moloney sarcoma that expresses Moloney sarcoma virus and carries 
the RT1 surface markers of the BN (3). 5 ×  104 MST-1 is lethal in irradiated recipient BN rats 
within 40 d. BM2 is another BN rat tumor line derived from MST-1. It expresses virus, elicits 
a  high level of cytotoxic effector cells, and is lethal in test-irradiated BN recipients at ~/dose 
7  that exceeds 10  cells. Both tumor lines are maintained in vitro as monolayer and suspension 
cultures. Passage numbers  10-40 of these lines were used both for immunizationof donor rats 
and as targets for S~Cr release assays in vitro. Immunization with either line protected recipient 
rats from lethal inocula of the other line. MST-1 was used in all experiments as the challenge 
tumor in vivo, and BM2 was usually used to immunize donor rats. 
Antibodies.  Three T  cell reagents were used to identify and to isolate rat T  lymphocytes: a 
monoclonal anti-rat T cell antibody (W3/13) and a second monoclonal anti-rat T cell antibody 
(W3/25), described by Williams et al.  (2)  and commercially available from Sera Lab, Ltd., 
Sussex, England. W3/13, by indirect immunofluorescence, i.e., by labeling cells with a fluores- 
cein  (FI)- or rhodamine (Rh)-labeled goat anti-mouse IgG (N. L. Cappel Laboratories, Inc., 
Cochranville,  Pa.)  after  binding  of  the  primary  unlabeled  antibody,  stained  100% of 
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thymocytes and 40-45% of spleen cells. W3/25 by indirect immunofluorescence, stained 95- 
100% of thymocytes and 35-40% of spleen cells, about 80-85% of cells stained by W3/13. This 
latter reagent detected  peripheral T  lymphocytes; W3/13 detected  peripheral and immature 
bone marrow and thymic T  lymphocytes (2).  A  rabbit anti-rat thymocyte antibody (RART) 
was prepared by injecting rabbits with rat thymocytes and absorbing the antiserum with rat 
liver,  kidney,  and  bone  marrow  until  <2%  of  the  bone  marrow  cells  stained  by  indirect 
immunofluorescence, and 90-95% of thymocytes were stained (4).  Cowan strain Staphylococcus 
aureus (Pansorbin; Calbiochem-Behring Corp., American Hoechst Corp., San Diego, Calif.) was 
coated with this antibody and was used to immunoprecipitate NP40 extracts of rat thymocytes. 
The antigen-antibody complex was injected to rabbits, and the resultant antiserum stained, by 
direct  fluorescence, 90-95%  thymocytes, 2-5% bone marrow  cells, and  40-50%  spleen cells. 
RART was used to lyse T-positive lymphocytes and destroyed 95% of thymocytes. 
Ia antigens were detected with a mouse antiserum, B 10.D2 anti-B 10.Br, generously supplied 
by Dr.  David Sachs  (5).  It  was used after  fractionation in 50%  ammonium sulfate.  Surface 
immunoglobulin (SIg) was identified with F(ab')2 fragments of a polyvalent goat antiserum to 
rat immunoglobulins (GARG); its preparation and properties have been described (6).  F(ab')2 
fragments of goat  antiserum to mouse IgG (GAMG)  (N.  L. Cappel  Laboratories, Inc.) were 
used  to detect  mouse IgG. GAMG was absorbed  with rat  IgG coupled to  Sepharose 4-B to 
render  it  specific  for  mouse  IgG;  labeled  with  a  fluorophore,  it  stained  1-2%  of rat  spleen 
lymphocytes by direct fluorescence assay. 
FI and Rh conjugates of anti-Ia, GARG, and GAMG were prepared as described elsewhere 
(7). 
Cell Staining.  T  lymphocytes were labeled by incubating 3 ×  l06 spleen cells or cells of a  7- 
d MLTC with  150/~g of GARG in a volume of 0.5 ml of minimal essential medium or RPMI- 
1640  (Grand Island Biological Co., Grand Island, N. Y.), supplemented with 10% fetal bovine 
serum. The incubation period was 75 rain at 37°C, to strip SIg from the cell membrane of rat 
B  ,'e~]~ and  to  prevent  any cross-reactivity of GAMG  for  rat  spleen  cells.  The  cells,  after 
incubation, were washed once in Hanks' balanced salt solution containing 2% bovine serum 
albumin (BSA) and 0.1% NAN3, resuspended in 50/~l of this medium, and then incubated for 
30  rain  at  4°C with  25 ~l of W3/13  at  1:10 dilution or W3/25  at  1:4 dilution. Cells were 
washed  two times, resuspended in Hanks' balanced salt solution containing BSA and NaN.~, 
incubated with  20/.tg of FI-GAMG for  30  rain at  4°C, and washed  three  times before final 
suspension in medium. When T  cells were fractionated in a  fluorescence-activated cell sorter 
(FACS), W3/25 stained cells were kept  in RPMI-1640  10% fetal bovine serum for the entire 
procedure. 
SIg was detected with FI-GARG as described previously (6).  Ia was detected by incubating 
3 ×  106 spleen cells or cells ofa 7-d MLTC in 0.l ml with 25/~g of Fl-anti-Ia for 30 min at 4°C. 
Cells were washed three times, fixed by addition of 4% paraformaldehyde, final concentration 
1%, washed once, and examined. Double labeling was carried out as follows: (a) for Ia and SIg, 
cells were first labeled with Rh-GARG to detect SIg, washed three times in Hanks balanced 
salt solution-10% rat serum and 0.1% NaN.~, and stained next with FI-anti-Ia; (b) for Ia and T 
antigens, cells were stained first with unlabeled W3/25 or W3/13 followed by Rh-GAMG to 
detect T  antigens, washed three times in Hanks'-10% mouse serum and 0.1% NAN3, and next 
stained with Fl-anti-Ia. 
Fluorescence Microscopy and Rapid Flow Microfluorimetry.  Cells were examined in a  Zeiss epi- 
fluorescence microscope with FI- and Rh-specific filters. The number of positively stained cells 
per  100  lymphocytes  was  scored  for  each  trial.  Doubly  labeled  cells  were  quantitated  by 
recording the number of positively stained cells with one fluorophore per I00 lymphocytes and 
the number of positively stained cells with the other fluorophore per  100 positive cells labeled 
with the first fluorophore. 
Fluorescence intensity and light scatter were determined in an FACS (FACS II; Div. FACS 
Systems, Beckton, Dickinson & Co., Oxnard, Calif.). The preamplifiers and laser beam were 
adjusted so that the fluorescence peak was at channel 280, and the scatter peak was at channel 
230  when 5 ~m fluorescent beads were  tested  (Coulter Electronics Inc., Hialeah,  Fla.). The 
coefficient of variation was about 10%. Cells in fluorescence channels 100-400 were classified as 
low  density,  and  400-1,000  as  high  density.  Percentage  of  cells  under  each  part  of  the E.  FERNANDEZ-CRUZ, B.  A. WODA, AND J.  D.  FELDMAN  825 
fluorescence histogram was determined by the formula: number of cells in specified fluorescence 
channels/total number of fluorescent cells multiplied by 100. Positive W3/25 ceils were isolated 
by sorting in the FACS at 4-5,000/s. Cells in channels 0-90 were deflected left, and those in 
channels 110-1,000 were deflected right. 
Depletion of B  and  T  Lymphocytes.  B  cells were  eliminated  from  effector  populations by 
adherence  to  plastic  Petri  dishes  coated  with  affinity  purified  F(ab')2  fragments  of goat 
antibodies to rat immunoglobulins according to method of Mage et al. (8). T cells were removed 
by lysis with an excess RART and guinea pig serum diluted 1:5 as a  source of complement. 
RART plus complement treatment reduced day 7 immune T  cells from 57 to 5%, as detected 
by W3/13. 
Generation of Effector Cells.  Rats were immunized by a subcutaneous injection with 10  e BM2 
cells. Spleen cells were removed 7 wk later, 2 wk after the tumors had completely regressed. To 
augment  cytotoxicity, immune  spleen cells were cultured in  vitro with  MST-1  tumor cells 
treated  with  50  pg/107  ceils/ml, of mitomycin  C  (Sigma Chemical  Co.,  St.  Louis,  Mo.). 
Pretreatment of tumor cells with trypsin (0.5 g trypsin plus 0.2 g EDTA/liter for 5 min at 37°C 
in 95%  air-5% CO2;  trypsin EDTA  (Flow Laboratories, Inc., Rockville, Md.) enhanced their 
immunogenicity as stimulating elements in the MLTC. The cultures were established in 75- 
cm  2 tissue culture flasks (Falcon Labware, Div. of Becton,  Dickinson & Co.)  at  a  ratio 5:1 
spleen (E):tumor cells (T) and incubated for 7 d under the conditions previously described (1). 
Cytotoxicity of spleen cells only from donor rats in which regression was complete could be 
augmented in vitro. 
5tCr Release Assay.  After 7 d of culture the cytotoxic spleen cell activity (CMC) was assessed 
in a  16-h siC-release assay as described previously (1). The 7-d cultures of immune spleen cells 
and mitomycin C-treated MST tumor cells (MSTMit) yielded the maximal CMC, ranging from 
80 to 84% specific 51Cr release at E:T ratios of 50:1  to 100:1.  In a microassay, 104 SlCr-labeled 
target cells were incubated at a ratio of50:1 with effector cells in 0.5-ml microtubes in a volume 
of 0.3 ml. 
Challenge of Established Sarcomas In Vivo.  Assay rats were irradiated with 400 rad whole body 
irradiation, and inoculated subcutaneously in the flank with 5 X  104-2..5 X  l0  s MST-I, a lethal 
inoculum within 30-40 d. The dose of tumor varied with different passages of MST-1, and 
assay rats were tested at 6-8 d when MST-I was 1-1.5 cm in Diam; at 12 d, when tumors were 
2.5 cm in Diam; and at 18 d postinoculum when tumors were 4-7 cm in Diam. Groups of three 
to five assay rats were infused intravenously with a single or repeated doses of unfractionated 
cytotoxic effector cells or control effector cells. In some experiments, fractionated populations 
were used: W3/25 + cells and W3/25- cells from immune spleen cultures of MLTC; T cell- and 
B cell-depleted immune effector populations. Tumor size was monitored by measuring with 
dial  calipers every  2-4  d  for  up  to  100  d.  Size was  recorded  as  the  product  of maximal 
perpendicular measurements and presented in square millimeters as the mean of a group. 
Results 
Effector Cells and Tumor Elimination In  Vivo.  In the first set of experiments, a  tumor 
inoculum of 2.5 X  105 MST- I was injected subcutaneously into the right flank of BN 
rats, which were  irradiated with  400  rad  total body irradiation. The  E:T ratio was 
varied from 50:1  to 400:1, calculated on the number of tumor cells inoculated on day 
0. On day 6, when tumors ranged between  1.0 and  1.5 cm in Diam and had a  blood 
supply (as determined by histologic examination in other experiments) effector cells 
from  7-d MLTC,  with  augmented  in vitro cytotoxicity, were infused intravenously. 
The results are shown in Fig.  1. 
When  1 ×  l0  s immune spleen cells were infused intravenously (E:T ratio of 400:1), 
MST-1  was eliminated within 20-30 days after infusion of effector cells. By infusion 
of 5  X  107 immune spleen cells intravenously (200:1, E:T), MST-I  was eliminated in 
40-48 d  after infusion of effector cells; by infusion of 1.25  ×  107 immune spleen cells 
intravenously (50:1  E:T)  and  2.5  ×  107 immune spleen cells intravenously (100:1  E: 826  ELIMINATION  OF SARCOMAS BY A SUBSET OF T  LYMPHOCYTES 
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Fro.  1.  Effect  of the intravenous (i.v.) infusion of varying numbers of immune spleen cells (Spc), 
with augmented cytotoxicity, in assay rats bearing a day-6-established  vascularized subcutaneous 
(s.c.) MST-1 sarcoma, 1.5 cm in Diam. Controls included infusion of: MST-1 tumor cells alone, 
MLTC cells from normal nonimmunized donors, and MLTC immune spleen cells incubated with 
an unrelated tumor (BC5). Data pooled from 4 separate experiments, i.e., 20 assay rats in each 
group. 
T),  there  may have been some delay in tumor growth,  but  MST-1  expansion was 
progressive, and all rats were dead 40 d  after tumor inoculation. Untreated controls 
with  tumor only, died  within 30  d  of tumor inoculation. In  rats  given cells  from 
normal or progressor donor spleens that were cultured for 7 d  in MLTC, growth of 
tumors was unaffected or enhanced. 
Fig.  1 reveals that despite infusion of large number of effector cells, a period of time 
was required (about 2 wk) before regression was recognizable. Furthermore, the larger 
the  number of effector  cells,  the  greater  and  sooner  the  effect  on  tumor  growth. 
Similar results were also obtained in assay rats that were not irradiated except  that 
tumor elimination was prolonged by several days  (data not shown). Irradiated rats 
were reported in this paper because rate of growth of tumors in irradiated rats was E.  FERNANDEZ-CRUZ, B.  A.  WODA, AND J.  D.  FELDMAN  827 
less variable than  in  normal  rats  and  because  in  a  small  proportion  of normal  hosts 
bearing a  tumor,  infusion of effector cells was inhibitory rather than  curative (1). 
In  a  second  set  of experiments,  subcutaneous  inocula  of MST-1  were  allowed  to 
expand  in size for  12 and  18 d  after inoculation, when they were over 2.5 and  5.0 cm 
in  Diam,  respectively. These data  are shown  in  Fig.  2.  The  larger the tumor  load  at 
the time of infusion of effector cells, the greater the number  of effector cells that  was 
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FIG.  2.  Elimination of malignant sarcomas,  2.5-7 cm in Diam, by infusion of immune spleen cells 
with augmented cytotoxicity. Assay rats bearing a  12-d-old sarcoma (0) were treated with a single 
infusion  of effector cells and assay rats bearing an  18-d-old malignancy were treated with repeated 
infusions  (A) of effector cells.  Data  pooled from  three separate experiments.  Each  point of the 
experimental groups represents  the mean of 6 assay  rats,  and each point of the control curves is 
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needed to eliminate the tumor. As before, there was continued growth of tumor for 
10-14 d after infusion of effector elements. Elimination  of a  12-d-old sarcoma required 
a  minimal dose of 3  ×  l0  s effector cells, and complete elimination was achieved 50- 
60 d  after injection. However, in 18-d-old sarcomas, the total number of effector cells 
needed  to  induce detectable  regression was  7.5  ×  l0  s,  given in  two  intravascular 
infusions. Two additiona! infusions of effector cells were administered even when it 
was apparent that MSF-1 was diminishing, in order to ensure that the tumor would 
not resume growth, Fig. 3 is a  photograph showing the size of the tumor in one assay 
rat  at  its  peak  size  on  day  27  after  inoculation of MST-1,  and  also  its  complete 
elimination by day 98.  There was  no recurrence in any of the  rats  cured of MST 
sarcomas, some of them having been followed for more than 18 mo. Furthermore, the 
treated rats retained the capability to reject a  lethal dose of MST- 1 when challenged 
1 yr later (data not shown). 
FI~. 3.  Photograph showing: (A) one assay rat bearing a lethal subcutaneous MST-1 sarcoma, 6 
cm in Diam, on day 27 after tumor inoculation. The test rat was treated with repeated intravenous 
infusions  of effector spleen cells (total -- 1.5 ×  109), beginning on day 18 after inoculation of tumor. 
(B) Elimination of the tumor 98 d after tumor inoculation and 80 d after infusion of effector cells. E.  FERNANDEZ-CRUZ, B.  A.  WODA,  AND J.  D.  FELDMAN  829 
Nature of Effector Cells.  The composition of spleen cells after removal from normal 
BN  rats  and  BN  rats  with  regressed  or  progressive  tumors  (day  0  of culture)  is 
presented  in Table  I. There were no significant  differences  in the percentages  of T- 
positive, Ig  ÷, and Ia  ÷ cells. The non-T, Ig- cells included macrophages  (5-10%)  and 
null cells and other unidentified elements, and this mixed population of cells was also 
not significantly  different  in relative numbers among the three groups of spleens.  It 
should  be  noted  that  spleens  of rats with  progressive  tumors were about  two times 
larger in weight  (2-3  g)  than were spleens of normal control rats or spleens from rats 
in which tumors had regressed, and yielded twice as many cells per spleen. 
After  7  d  of culture of a  mixture  of spleen  cells  and  mitomycin-treated  MST-1, 
there was a significantly altered composition of spleen cells from regressor rats (Table 
I). T  cells were selectively increased  (50-57%),  Ig  ÷ cells were decreased;  and Ia  + cells 
were  increased.  The  total  number of cells  in  7-d  cultures  of spleens  from regressor 
animals averaged  50%  of the number cultured  on  day 0;  in  7-d  cultures  of spleens 
from normal rats or rats with progressive tumors, cells were reduced to 15% of the day 
0  number.  The  relative  percentages  shown  in  Table  I,  indicate  that  there  was  a 
fivefold increase of W3/25 + cells in day 7 cultures of regressor spleens compared with 
day  7  cultures  of controls.  For in  vivo  infusion,  experimental  and  control cultures 
were  pooled.  When  an  equal  number  of cells  was  administered  to  tumor-bearing 
hosts,  the absolute  number of W3/25 +  T  cells  in  pools of regressor spleen  cultures 
delivered  to  test  rats,  was  significantly  greater  than  the  number  of W3/25 +  cells 
delivered  in  pools of cultures  derived  from controls or uncultured  regressor spleens. 
Examination  of  spleens  from  normal  rats  and  rats  with  progressive  tumors  also 
revealed that  after 7 d  of culture in MLTC,  there was a  relative decrease of T  cells, 
Ig  +,  and  Ia  + cells.  These  decreases were not statistically  significantly  different  from 
the percentages of cell types found in day 0 cultures. 
There was also a significant  increase in the number of Ia  + cells in the 7-d cultures 
of regressor spleens. Approximately  55% of W3/25 + T  cells became Ia  +  (Table I). In 
the  three  groups  of spleens  at  day  0,  Ia  ÷  T  cells  ranged  from  1  to  3%.  Our  data 
TABLE  I 
Surface Markers on Uncultured and Day 7 ML TC Cells* 
T 
T  (W3/13')  T  (W3/25 ÷)  1,~  +  la+  T  (W3/13 ~) la +  T  (W3/25 *)  la + 
,/,, 
Uncultured  spleen  cells, 
day 0 
Normal  splc<'ns  45 ±  I  (41§  38 ±  I  (4) 
Progncs+sor  sl)lcens  46 +  2  (41  34 +  2  (4) 
Regressor sl)leens  46 ±  I  (4)  38 ±  I  (4) 
I)a)  7  MI.FC  cells 
Normal  sl)leens  39 ±  3  (3)  35 ±  3  (3) 
pIIOg[lt~l" splcens  37 ±  6  (3l  ,  35 ±  3  (31 
Rcgres.s,a~  spleens  57 ±  3  (6)  50 ±  3  (61 
rll  /' =  o..2  /' <  o.o~ 
48  ±  2  (4) 
46 ±  (4) 
45 ±  (4} 
31  ±  (2) 
39+  2  (2) 
24 ±  (i (4) 
P<I).02 
27 ±  I  (12)  3  +  I  (7)  2  ±  1 (7)  7 
28 +  I  (2)  4  ±  L (2)  4  ±  ]  (~)  8 
29 :t:  I  (2)  5  ±  I  (2)  4  +  I  (2)  9 
18  (I)  I  (I}  2  (I)  30 
21  +  2  (2)  5 ±  I  (2)  4  +  2  (2)  24 
58 ±  4  (5)  54 :t:: 7  (4)  55 ±  7  (4)  1'9 
P  <  (J,OI  P <  O.(Jl  P  <  [).OI 
* Data  shuwn  are the mean l)<'rcentage of stained  cells ±  SEM. 3  x  I0  + uncuhured  and  day  7 MI,TC Sl+dC<.'l+  cells were ~;tainetl with Fl-GAR(;, 
anti-W3/13,  of"  anti-W3/2-)  fi)ll,awcd  hy  FI-(;AMC;.  I  X  I(('  viabLe  celLs  were  analyzcd  f,~.  f]tlOl'e~¢..'~llC~  '  intensity  in  a  FACS.  For' the 
drterminalitm  of [a-positive  cells and  ]a-ix~sitlvr T  cells, 3  ×  10  s cells wctc  stained  with  anti-W3/13 or anti-W3/25 and Rh-GAM(;  ftfllowcd 
by F I-anti-|a.  Tile i~..rcentage of la-lz.Ositive lymphoid  cells and  la-positive  T  cells was determitv:d  by fluorcscenct:  micl,.~sc,.)l)y. 
:~ Dt'tcrmhled  by subtracting  fi'om  I(X)'7, the  t,,~tal  number  oft  cells  (W3/i3")  and  B  cells ([g+), 
§  Numbel of trials in parentheses. 
II e  value was calculated  by Studem's  t test and compares  uulculttued  (day 01 legu'ess<,  spleen celN and day 7  MI.TC  regressor spleen cells+ 830  ELIMINATION OF SARCOMAS BY A SUBSET OF T  LYMPHOCYTES 
apparently  underestimated  the  total  number of Ia  ÷ cells  present  on  days 0  and  7. 
Fluorescence microscopy of day 0  spleen cells showed that  about  30%  are Ig  ÷, and 
90% of the Ig  ÷ cells are Ia  ÷. FACS analysis showed that 48% of cells are Ig  ÷, hence, 
Ia-positive cells could be expected to be about 40%. 
Microscopic  examination  of  7-d  cultures  disclosed  that  75%  of  the  cells  were 
blastlike  cells  (Fig.  4):  there  were  very  few  tumor  cells  and  macrophages.  With 
appropriate staining, of the blast cells 65% were T  cells;  there were also about  10% 
Ig  ÷ cells. In 7-d cultures of progressor and normal spleens, there were relatively large 
numbers of tumor cells,  few blast cells, and some large vacuolated elements, which 
may have been macrophages (Fig. 4). A light scatter histogram disclosing the change 
in  cell size of 7-d MLTC cultures  of regressor spleens confirmed a  significant  shift 
from small to large cells. Over 70% of day 7 cultures were larger than average spleen 
cells of day 0 cultures (data not shown). 
The observations recorded  in  Table I  and  Fig.  4  implicated T  cells as the  main 
effector ceil'population. T  cells were, therefore, reacted with W3/13 and W3/25 anti- 
T  reagents  and  examined  in  a  FACS  for staining  intensity,  i.e.,  for  density  of T 
antigens on T  cell surfaces. Cultures,  prepared immediately after removal of spleens 
from donor rats and from cultures of 7-d MLTC, were labeled. Results are shown in 
Fig.  5 and Table II. In Table II cells were analyzed for their fluorescence intensity: 
low intensity channels  100-400, and high intensity, channels 400-1,000.  The signifi- 
cant change in the day 7 effector cell population was an increase of poorly stained T 
cells and  a  significant  decrease of brightly stained  cells when  F~-W3/13  was  used. 
This decrease in fluorescence intensity occurred on cells that had increased in size as 
determined by light scatter. The opposite changes occurred when FI-W3/25 was used 
(Fig. 5). 
Elimination  of Tumor  In  Vivo with  Fractionated  T  Cells.  Day  7  cultures  of MLTC 
derived  from  regressor  spleens  were  sorted  in  a  FACS  into  W3/25 +  and  W3/25- 
populations.  W3/25  by indirect  immunofluorescence identified  87%  of total  day  7 
immune  T  cells.  Of  the  W3/25 +  populations,  95%  were  positively  stained  after 
examination of sorted ceils, and 55% were Ia  ÷. Rats were infused intravenously with 
5  ×  106 W3/25 ÷ cells,  with  equal  numbers  of W3/25-  cells,  or with  10-15  ×  106 
immune spleen cells of 7-d MLTC, stained  with W3/25  but  not sorted.  The latter 
unfractionated  population contains approximately 5-7.5  ×  106 W3/25 ÷ T  cells and 
5-7.5  ×  106 W3/25- cells.  The results of one such experiment are shown in  Fig.  6. 
With infusion of W3/25 + T  subset, an inoculum of 105 MST given subcutaneously 6 
d  before was completely eliminated  in 6-8 d. W3/25-  cells were ineffective against 
the established tumor; indeed,  MST was significantly larger than  tumors in control 
rats.  10-15  ×  106 unfractionated  day  7 immune spleen cells inhibited,  but  did not 
eliminate,  the  tumor. This type of experiment  has been  performed four times with 
similar results. However, when the sorted W3/25 + T  lymphocytes could not be infused 
in sufficient numbers into rats bearing a  0.7- to  l-era sarcoma, growth of the tumor 
was inhibited,  but MST was not eliminated;  the challenged hosts survived 75-95 d. 
In  assay rats  treated  with  W3/25-  cells,  tumors were  larger  than  in  controls,  and 
challenged hosts survived 28-30 d. Mean survival time in untreated controls was 38 
±4dSE. 
A  number  of  other  fractionated  populations  of  effector  cells  were  assayed  as 
described above.  10-50  ×  106 immune spleen cells deprived of T  cells by lysis with E.  FERNANDEZ-CRUZ,  B.  A.  WODA,  AND J.  D.  FELDMAN  831 
Fro.  4.  (A)  Photomicrograph of effector cells in 7-d MLTC containing immune spleen cells from 
donor with regressed tumor and  MST-lstit. Blast lymphocytes are numerous and tumor cells are 
rarely encountered. Giemsa stain; cytocentrifuged preparation; ×  250.  (B) Photomicrograph of cells 
in 7-d MLTC containing immune spleen cells from donor with progressing tumor and MST-1Mit.  A 
mixture of tumor cells  (arrows)  and  small  lymphocytes are seen. Giemsa stain;  cytocentrifuged 
preparation. ×  250. 832  ELIMINATION  OF  SARCOMAS  BY  A  SUBSET  OF  T  LYMPHOCYTES 
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Fxc.  5.  Fluorescence histograms of day 0 and day 7 MLTC.  10  '5 immune spleen cells, from a donor 
with a  regressed tumor were reacted with W3/25  and  FI-GAMG. Cell number is plotted on the 
vertical axis, fluorescence imensity on the horizontal. There is a marked increase of W3/25 antigen 
after 7 d in culture. 
TABLE  II 
Fluorescence Intensity of Stained Spleen Cells* 
Fluorescence  Regressor,  Regressor,  P:I: 
channel  Normal, day 0  day 0  day 7 
% 
T  (W3/13 +) 
100-400  69 ±  4 (4)§  67 +  4 (4)  85 +  4 (4)  <0.02 
400-1,000  31  ±  5 (4)  32 ±  2 (4)  15 ±  2 (4)  <0.00l 
T  (W3/25 ÷) 
100-400  92 ±  2 (4)  94 ±  2 (4)  72 ±  4 (7)  <0.01 
400-1,000  7 ±  1 (4)  5 ±  1 (4)  28 ±  4 (7)  <0.0l 
* Data shown are the percentages of SEM of fluorescent cells present in the 
specified channels. 3 X  [0  t~ uncuhured and day 7 MLTC spleen cells were 
incubated with anti-W3/13  or anti-W3/25  and stained with FI-GAMG.  1 
×  10  .5 viable cells were analyzed for fluorescence intensity in a  FACS. The 
percentage of cells under each portion of the curve was determined as follows: 
cells in specified fluorescence channels/total fluorescent cells :x:  100. 
~: P value was calculated by Student's t test and compares uncultured (day 0) 
regressor spleen cells and day 7 MLTC regressor spleen cells. 
§ Number of trials in parentheses. 
RART  and  complement  (C)  were  ineffective against  MST  (Fig.  6).  At  an  E:T  ratio 
in  vivo  of  1,000:1  (1  ×  108  immune  spleen  cells),  the  tumor  was  inhibited  but  not 
eliminated  (5-7%  T +  cells remained;  data  not shown).  50  ×  106 immune  spleen cells, 
after reduction  of SIg  + cells to 3% of the total, completely  eliminated  MST-1  in about 
40  d,  a  result  similar  to  that  obtained  with  unfractionated  day  7  effector  cell E.  FERNANDEZ-CRUZ,  B.  A.  WODA,  AND J.  D.  FELDMAN 
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Fro.  6.  Effect of W3/25 ÷ and W3/25- immune spleen cells on tumor growth in vivo. Each curve 
represents one trial. Similar results were obtained in four different experiments (total =  four assay 
rats)  with W3/25 + and  W3/25-  cell  fractions, but  these data  are not  pooled because different 
numbers of sorted cells and different doses of tumor challenge were used in each experiment. The 
growth curves of tumors treated with unfractionated cells, of controls, and of tumors treated with 
T-depleted immune spleen cells represent the mean of three different experiments with three assay 
rats per group (nine observations per point). 
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populations.  A  (W3/13 +,  W3/25-)  T  cell  population  could  not  be  obtained  in 
sufficient numbers to infuse into tumor-bearing rats. 
In Vitro Cytotoxicity of Fractionated T Effector Cells.  Immune spleen cells of 7-d cultures 
in MLTC  were sorted in a  FACS into W3/25 + and W3/25- populations. These and 
the  unfraetionated  cultures  containing  W3/25 +  and  W3/25-  populations 
were tested  for cytotoxicity against  target  MST-1  in 51Cr release assays.  Fig.  7 gives 
the  results  of these  experiments  and  represents  the  mean  of three  trials,  each  trial 
carried out in triplicate;  the standard error of the mean did not exceed  10% for these 
experiments.  W3/25 + cells were poorly cytotoxic; cytotoxicity ranged from 11 to 13% 
specific 51Cr release. W3/25- cells were more effective, displaying 22-50% specific 51Cr 
release. The unfractionated mixed population from which W3/25 + and W3/25- were 
derived,  under similar  experimental  conditions,  yielded  specific ~ZCr release  of 37- 
62%  at  ratios  of 20:1  to  50:1.  Also,  removal  of T  lymphocytes by  treatment  with 
RART  and  C  decreased  in  vitro  cytotoxicity to 
cytotoxic against  MST  (average 70% 51Cr release 
Cytotoxicity of unfractionated  immune spleen 
mycin C-treated  MST  (MSTMit)  was augmented 
less  than  10%.  W3/13 +  cells  were 
at an E:T of 50:1). 
cells,  incubated  for 7 d  with  mito- 
to 60-70% 51Cr release;  at the time 
of removal  from donor rats,  immune spleen  cells showed a  10%  51Cr release against 
MST  (1).  Control  spleen  cells,  immune  spleen  ceils  cultured  without  antigenic 
stimulation, and immune spleen cells cultured with an unrelated tumor (BC5), showed 
no augmentation of~Cr release after 7 d  in culture, and were ineffective in vitro and 
in vivo against  MST  (1). These results indicate that in vitro culture with the specific 
tumor antigens is necessary to augment effector function of infused cells. 
Discussion 
There  has  been a  plethora  of reports  describing either  protection,  prevention,  or 
elimination in vivo of syngeneic or allogeneic tumor by injection of cytotoxic effector 
70 
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FIG.  7.  In vitro cytotoxicity of W3/25 + and W3/25- immune spleen cells of 7-d MLTC and the 
unfractionated population from which these were derived. Immune spleen cells and control spleen 
cells were tested in a nJCr release assay against MST-I. Day 7 control spleen cells expressed negative 
cytotoxicity (data not shown). Each point is the mean of three trials in three separate experiments 
(nine observations) at E:T ratios of 20:1 and 50:1. E/Tu, spleen (E):tumor cells (Tu). E.  FERNANDEZ-CRUZ, B.  A. WODA, AND J.  D.  FELDMAN  835 
cells, i.e., immune lymphoid cells (9-73). The tumors have been lymphomas, leuke- 
mias, plasma cell tumors, fibrosarcomata, mammary, and lung carcinomas, and they 
have  been  induced  by  RNA  C-type viruses,  DNA  simian  virus  40,  and  chemical 
carcinogens.  The  test  species  have  included  mice,  rats,  and  guinea  pigs  (we  are 
excluding human trials in this report). In most instances, malignant tumors have been 
prevented  from  growing  by  administration  of immune  lymphoid  cells  before  or 
simultaneously  with  the  inoculation  of  transplantable  tumor  or  inducing  virus. 
However, a  number of papers described  the elimination  of tumors after they have 
been inoculated into test animals, usually 3-5 d before administration of effector cells 
(14,  15,  17,  19, 20, 23-26, 28, 31, 46, 56, 57, 62, 70,  73) when the tumors ranged from 
0.5 to 2.0 cm in Diam. In some models combined immuno- and chemotherapy have 
been applied (19, 22, 24-26, 30, 31, 48, 50, 51, 59, 62, 63). 
In  our  model,  established  sarcomas  of large  size  (1-7  cm)  and  relatively  long 
duration  (18 d) were completely and permanently eliminated, by remote infusion of 
syngeneic effector T  lymphocytes that were stimulated a  second time by the specific 
antigen, i.e., by MST-1 tumor. Several rough calculations reveal that a 5-cm in Diam 
5-g tumor is about 3% of the body weight (165 g) of the test rats bearing the tumors. 
If translation to human proportions is permissible, this represents a 2-kg neoplasm in 
a  70-kg adult.  In  addition,  tumors were expanding  for  18  d  before treatment  was 
started; jn  100-d-old test rats, this is 18% of their lives, or in human terms, about 3.5 
yr of a 20-yr-old adult. Regression of these large tumors (5-6 g), which we estimate to 
contain not less than 5 x  l0  a viable tumor cells, was visible after infusion of 7.5  x  l08 
effector cells, which is about two times the number of cells that can be recovered from 
an adult BN spleen. The W3/25 ÷ effector population was about 4 ×  108 cells. 
The subset associated with elimination of established tumors was defined by W3/ 
25 +, W3/13 ÷ blast cells. However, in vitro this subset was poorly cytotoxic for MST- 
1. These disparate results suggested that the (W3/25 ÷, W3/13 ÷) T  cell functioned as 
a  helper or amplifier cell in the tumor-bearing host and that elimination of MST-1 
required  participation by the host. In support of this was the following observation. 
There was a  time lag between infusion  of effector cells and noticeable regression of 
tumor.  If W3/25 ÷,  W3/13 +  cells  were  directly  cytotoxic  in  vivo, one  might  have 
expected an immediate or almost immediate effect on tumor size. Instead, there was 
continued tumor expansion for 10-14 d after effector cell infusion. In addition, White 
et al.  (74)  have provided some evidence that  the W3/25 ÷ cell functions as a  helper 
cell.  However,  we  cannot  exclude  the  possibility  that  the  W3/25 ÷  cell  may  be 
converted to a cytotoxic effector cell after transfer to the assay animal, or that a small 
number of cytotoxic cells contained in the effector cell population expand to kill the 
tumor. 
The  biological significance of the surface membrane markers on  the cells of the 
effector subset  is  still  undefined.  In  the  MLTC,  a  T  cell  subset  was  expanded  in 
response to tumor antigens and transformed into blast elements. With these changes 
there was an increase in the W3/25 antigen on the cell surface and a decrease of W3/ 
13  antigen.  We have not  determined whether the W3/25 + antigen  is obligatory for 
helper function and whether its presence determines function or vice versa. Ia antigens, 
at least the ones detected by the antiserum used, seem not to be related to the in vitro 
function of W3/25 ÷ cells. In preliminary experiments when immune spleen cells of 7- 
d  cultures  were depleted  of Ia-positive cells by anti-Ia antibody plus C  or when  Ia 836  ELIMINATION OF  SARCOMAS  BY  A  SUBSET  OF  T  LYMPHOCYTES 
antigens were stripped from the lymphocyte membrane by capping, in vitro cytotox- 
icity was the same as that observed with populations that were Ia  +.  Several recent 
reports have emphasized that Ia antigens of the I-A region of major histocompatibility 
complex are associated with amplifier T  cells (75, 76); other reports indicate that Ia 
antigens, particularly those related to the I-J region, are associated with cytotoxic T 
cells (77-79). Ia antigens may merely be a differentiation marker or a marker for cell 
activation (75, 80-83). In our model, the acquisition of Ia during MLTC appears to 
have a  positive relationship with cell activation because cell cultures  from normal 
spleens, from spleens derived from rats with progressive tumors, and from regressor 
donor  spleens  that  failed  to  become  cytotoxic and  to  eliminate  tumors  in  vivo, 
contained  only  3-5%  Ia  +  T  cells  and  also  very few T-blast  forms.  The  W3/25- 
population was associated with enhancement of MST-1  in vivo and with moderate 
cytotoxicity for MST-1 in vitro. The W3/25- population was a melange of cells that 
included  (W3/13  +, W3/25-)  T  cells (about  14% of this population), null cells, Ig  + 
cells, and  1-3% macrophages. Suppressor cells were likely contained in the W3/25- 
population, as is suggested by the tumor enhancement in vivo and by the failure of 
small  numbers of unfractionated cells  (containing a  mixture of 5-7  X  10  n W3/25 ÷ 
and 5-7 ×  10  n W3/25-) to eliminate tumor as shown in Fig. 6. However, this possible 
inhibitory effect would be overcome when higher numbers of unfractionated cells are 
used  (Fig.  1).  The  phenotype of the  suppressor  element  has  not  been  identified. 
Suppressor T  cells have been shown to operate in a  model in vivo with established 
tumors  (73). We also have not ascertained the cytotoxic cell contained in W3/25- 
population. The in vitro cytotoxicity results suggest that one of the cytotoxic cells is 
a W3/13 + T  cell. A null cell with antibody to viral antigens might also be operative 
(E. Fernandez-Cruz and J. D. Feldman. Unpublished observations.). 
Our observations in this in vivo tumor model suggest that successful elimination of 
an  expanding  tumor  depends  upon  a  balance  of helper  cell  activity  overriding 
suppressor cell activity with participation of the host to provide the cytotoxic elements. 
If there are insufficient helper cells or too many suppressor elements, there will be no 
participation by the host and no provision of cytotoxic cells. The manipulations and 
use of immune effector cells in  this rat  model  are applicable to human  neoplastic 
conditions. With methods available to grow T  cell lines with specific reactivities (81, 
84-87), it is conceivable that a T  lymphocyte subset could be isolated from peripheral 
blood or draining lymph nodes of humans bearing tumors and could be cultivated in 
vitro into permanent cell lines. These T  cell lines, selected by their specific anti-tumor 
reactivities, could be returned to the tumorous patient in any number of effector cells 
needed. 
Summary 
Established  subcutaneous  Moloney  sarcomas  (MST-1)  of  large  size  and  long 
duration  were  eliminated  from  syngeneic rats  by  intravenous  infusion  of varying 
numbers of specific syngeneic effector T  lymphocytes. Spleen cells from BN rats in 
which tumor had regressed were cultured in an in vitro mixed lymphocyte tumor cell 
culture  (MLTC)  to augment  cytotoxieity of effector cells.  In  the  MLTC: a  T  cell 
subset  was  expanded  in  response  to  MST-1  antigens  and  transformed  into  blast 
elements. With these changes, there was an increase in the W3/25 antigen on the T 
cell surface, a  decrease of W3/13 antigen, and an increase in the number of T  cells E.  FERNANDEZ-CRUZ, B.  A. WODA, AND J.  D.  FELDMAN  837 
with Ia antigens. The subset associated with elimination of established tumors was a 
blast T  celt W3/25 ÷, W3/13 +, as detected by monoclonal antibodies to rat T  antigens. 
The  W3/25 +  subset  was  poorly cytotoxic in vitro for MST-1  and  apparently func- 
tioned in vivo as an amplifier or helper cell in the tumor-bearing host. The W3/25- 
population was a  melange of cells that included (W3/13 +, W3/25-) T  cells, null cells, 
Ig  + cells, and macrophages, and was associated with enhancement  of tumor in vivo, 
suggesting the presence of suppressor cells. 
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